Brief: Torrent Pharma Says USFDA Conducted Routine GMP Inspection Of Formulation Manufacturing Facility
Sept 20 (Reuters) - Torrent Pharmaceuticals Ltd
TORP.NS :
* USFDA CONDUCTED ROUTINE GMP INSPECTION OF FORMULATION
MANUFACTURING FACILITY
* END OF INSPECTION, AGENCY ISSUED FORM FDA 483 WITH ONE
OBSERVATION
* FORM FDA 483 WITH ONE OBSERVATION IS PROCEDURAL IN NATURE
Source text for Eikon: ID:nBSE9Dt3XX
Further company coverage: TORP.NS
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Torrent Pharmaceuticals
See all newsHSBC sees steady growth for India healthcare; raise TP on Dr. Reddy's
India's Torrent Pharma's profit slips as R&D costs outweigh domestic demand
Brief: Torrent Pharma Q2 Consol Net Profit 5.34 Billion Rupees
GLP-1 boom in China, India, Brazil could create $22 bln market by 2035, J.P. Morgan says
India's Torrent Pharma Q2 earnings to get an acquisition lift, Nomura says